Stock Analysis
Align Technology IncALGN
P/E 25.30×· 5Y range 20.86–94.33×· bottom 5% of history
Sector: Healthcare · Industry: Orthopedic, Prosthetic & Surgical Appliances & Supplies
AnalystsBuy25 analystsP/E 25.3× sits at the 5th percentile of its 5.089664613278576-year history.
PMP Verdict
Mixed fundamentals, cheap valuation
Strengths
- Quality85
- Financial Health62
Risks
- Growth31
- Profitability49
Mixed business trading cheap — priced for skepticism.
Bull Case
- ✓Altman Z 4.6 — safe-zone balance sheet
- ✓Interest coverage 38.9× — debt well covered
- ✓P/E 25.3× at bottom 5% of 5-year history
What's happening with ALGN
Profile
Strong moat, earnings quality and valuation; growth and profitability lag behind.
How is each axis scored?
- Valuation75/100 · Strong
- P/E vs own history (5th pct)25/25
- FCF yield (6.1%)20/25
- P/S (2.5x)20/25
- EV/EBIT (n/a)10/25
- Growth31/100 · Weak
- Revenue CAGR (0.5%)6/25
- Net income CAGR (-14.6%)0/25
- EPS CAGR 5Y (-12.6%)0/25
- Fwd implied growth (101.4%)25/25
- Profitability49/100 · Weak
- ROIC (14.6%)12/25
- ROE (10.2%)12/25
- Net margin (10.0%)13/25
- Operating margin (13.2%)12/25
- Financial Health62/100 · Moderate
- Altman Z (4.56)25/25
- Current ratio (1.36)12/25
- Interest coverage (38.9x)25/25
- Net cash / debt (n/a)0/25
- Quality85/100 · Strong
- Piotroski F (6/9)15/25
- Beneish M (-2.54)25/25
- FCF conversion (153%)25/25
- Margin stability (σ 5.3%)20/25
- Moat93/100 · Strong
- ROIC >12% years (10/10 yrs)25/25
- Median gross margin (71.9%)25/25
- FCF-positive years (10/10 yrs)25/25
- Worst-year net margin (worst 9.7%)18/25
About Align Technology Inc
Align Technology is the leading manufacturer of clear aligners. Show more
Invisalign, its main product, was approved by the Food and Drug Administration in 1998 and has since dominated, controlling over 90% of the market. Invisalign can treat roughly 90% of all malocclusion cases (misaligned teeth), and there are over 230,000 Invisalign-trained dentists and orthodontists. In 2022, Invisalign treated over 2 million cases, or roughly 10% of all orthodontic cases for the year, and it has treated over 14 million patients since its launch. Align also sells intraoral scanners under the brand iTero, which captures digital impressions of patients' teeth and illustrates treatment plans. Over 85% of Invisalign cases are submitted by digital scans, and iTero scans make up over half of these scans.
Headquarters: TEMPE, AZ · Employees: 20,435 · Website ↗
Price History
Weekly Candlestick Chart — up to 5Y
Key Metrics
Financial snapshot · Tap any metric for its definition and grade
TTM Snapshot
trailing twelve months · YoYValuation
75B+P/E (TTM)25.3xC
Grade C: ExpensivePrice / TTM EPS (own statements) — vs own 5Y history: 20.9x–94.3x · 5th pct
P/FCF16.6xB
Grade B: FairPrice / Free Cash Flow per share (Finnhub). Inverse of FCF yield — negative when FCF is negative
FCF Yield6.1%A
Grade A: ValueTTM (OCF − CapEx) / Market Cap — vs own 5Y history: 1.2%–6.9% · 96th pct
P/S (TTM)2.53xB
Grade B: FairPrice / TTM Revenue (own statements) — vs own 5Y history: 2.3x–16.7x · 5th pct
EV/EBITDA11.7xA
Grade A: CheapEnterprise value / EBITDA (Finnhub) — capital-structure neutral
EV/Sales2.3xB
Grade B: FairEnterprise Value / TTM Revenue (Finnhub) — capital-structure neutral sales multiple
Forward P/E12.6xA
Grade A: CheapPrice / next-year EPS estimate — shows whether the TTM multiple is rich or just front-loading growth
P/B Ratio2.59xA
Grade A: FairPrice to Book Value. Neg. equity = heavy buybacks
PEG Ratio2.88C
Grade C: ExpensiveFinnhub PEG — their P/E basis ÷ expected EPS growth. Suppressed when their P/E diverges >2× from our TTM P/E (different basis)
Dividend Yield—
TTM dividend yield (Finnhub) — annual dividends / price. None = no dividend; very high yield can signal distress
Payout Ratio—
Dividends / Net Income (Finnhub) — share of earnings paid out; >90% or negative = unsustainable
Profitability
49D+ROIC14.6%C
Grade C: AverageNOPAT (EBIT less ~21% tax) / invested capital (equity + debt − cash). Flagship quality metric — durable >15% signals a moat
ROE10.2%C
Grade C: AverageReturn on Equity. Neg. equity = heavy buybacks
ROA6.6%C
Grade C: AverageReturn on Assets (Finnhub) — Net Income / Total Assets; how efficiently assets produce profit
Net Margin10.0%C
Grade C: AverageNet Income / Revenue
Operating Margin13.2%C
Grade C: AverageTTM EBIT / TTM Revenue
Gross Margin68.0%A
Grade A: PremiumGross Profit / Revenue
FCF Margin15.3%A
Grade A: HighFCF / Revenue
True FCF Margin11.0%C
Grade C: AverageTTM (OCF − CapEx − SBC) / TTM Revenue — SBC treated as a real cost
Growth
31DRevenue CAGR0.5%D
Grade D: LowCompound annual revenue growth (up to 5Y depending on data availability)
Net Income CAGR-14.6%D
Grade D: LowCompound annual net income growth (up to 5Y depending on data availability)
EPS CAGR (5Y)-12.6%D
Grade D: LowCompound annual EPS growth over up to 5Y of per-share earnings (own statements). Null when either endpoint EPS ≤ 0
Implied EPS Growth101.4%A
Grade A: HighAnalyst forward EPS (normalized basis) vs our GAAP TTM EPS — different bases, so extreme values usually mark cyclically depressed TTM earnings, not real growth
Dilution (5Y)-10.9%A
Grade A: BuybacksShare count change over 5Y
SBC / Net Income43.3%D
Grade D: HighStock-based comp/Net income. >30% = dilution risk
SBC / Revenue4.3%C
Grade C: MedTTM stock-based comp / TTM Revenue
Financial Health
62BAltman Z-Score4.56A
Grade A: SafeBankruptcy risk. >3 Safe, <1.8 Distress
Current Ratio1.36xC
Grade C: OkCurrent Assets/Liabilities
Quick Ratio1.23xA
Grade A: High(Current Assets − Inventory) / Current Liabilities (Finnhub) — stricter liquidity test, excludes inventory
Interest Coverage38.9xA
Grade A: StrongEBIT/Interest. >10 Strong
Debt Repayment—
Years to repay net debt via FCF
Net Debt/EBIT—
Leverage. <2x Low, >4x High
Debt/Equity0.00xA
Grade A: LowDebt / Equity: <1 Conservative, >2 Risky. Not meaningful with non-positive equity; shown as unavailable rather than low debt.
Cash / Debt—
Cash covers how much of total debt. >1 = could repay all debt from cash
Quality
85APiotroski F-Score6/9C
Grade C: AverageFinancial strength 0–9. >7 Strong
Beneish M-Score-2.54A
Grade A: SafeEarnings manipulation risk. < -2.22 Safe
FCF Conversion153.2%A
Grade A: StrongFCF / Net Income
Margin Stability5.3%A
Grade A: StableEBIT margin std deviation. Lower = stable
Capex / Revenue3.0%A
Grade A: Asset-lightTTM CapEx / TTM Revenue — high % = capital-hungry business
Asset Turnover0.66xC
Grade C: AverageRevenue / Total Assets (Finnhub) — how efficiently the asset base generates sales
Insider Transactions
SEC Form 4 · 8 recordsP/S codes are the directional signal; grants, option exercises and tax withholding carry none. Form 4 doesn't flag 10b5-1 plans — scheduled sales may appear within open-market sells.
| Trade date | Insider | Transaction | Shares | Filed |
|---|---|---|---|---|
Blackford Quentin S. Filed | Blackford Quentin S. | Grant / award | +1.4K | |
Vitalone Britt J. Filed | Vitalone Britt J. | Grant / award | +1.8K | |
Vitalone Britt J. Filed | Vitalone Britt J. | Option exercise | -1443 | |
Vitalone Britt J. Filed | Vitalone Britt J. | Option exercise | +1.4K | |
SIEGEL SUSAN E Filed | SIEGEL SUSAN E | Grant / award | +1.8K |
Show 3 more filingsShow fewer filings
| Trade date | Insider | Transaction | Shares | Filed |
|---|---|---|---|---|
SIEGEL SUSAN E Filed | SIEGEL SUSAN E | Option exercise | -1745 | |
SIEGEL SUSAN E Filed | SIEGEL SUSAN E | Option exercise | +1.7K | |
Saia Andrea Lynn Filed | Saia Andrea Lynn | Grant / award | +1.8K |
Option exercise (M) rows report a derivative leg, not an open-market sale — a paired negative entry is the option position being consumed.
More metrics — Moat, Per Share, Balance Sheet, MarketHide additional metrics
Moat
93A+ROIC >12% Years10/10 yrsA
Grade A: DurableShare of completed fiscal years with ROIC > 12% — measures multi-year capital-return durability
Gross Margin (Med.)71.9%A
Grade A: DurableMedian annual gross margin across available fiscal years — pricing-power durability
FCF-Positive Years10/10 yrsA
Grade A: DurableShare of completed fiscal years with positive free cash flow
Net Margin Floor9.7%A
Grade A: DurableWeakest annual net margin across completed fiscal years — recession/downcycle resilience
Per Share
EPS (TTM)$5.82
Own TTM net income / shares — same earnings basis as P/E
Cash / Share$15.48
Cash & short-term investments per share (Finnhub)
Book Value / Share$59.41
Shareholders' equity per share (Finnhub). Negative = accumulated losses / heavy buybacks
Balance Sheet
Total Debt—
Total debt obligations (short + long term)
Cash & Equiv.$1.09B
Cash and short-term investments
Net Debt—
Total Debt minus Cash. Negative = Net Cash position
Total Equity$4.05B
Shareholders' equity (book value)
Asset / Liability2.85xA
Grade A: SolidTotal Assets / Total Liabilities
Market
Market Cap$10.47B
Current Market Capitalization
Beta1.74C
Grade C: VolatilePrice sensitivity vs the market (Finnhub) — 1.0 moves with market, >1.2 amplifies swings
How grades work: each metric is graded A–D against fixed thresholds (tap a row for the meaning). Card grades map the pillar score to A+–E — a card grade is that pillar's own score, not an average of the rows shown.
Financials as of Jun 2026 · Ratio snapshot Oct 17, 2026
Key Insights: Align Technology Inc (ALGN)
ALGN is down 1.36% at the last close. Piotroski F-Score of 6/9 indicates mixed fundamentals for Align Technology Inc. Altman Z-Score of 4.56 sits comfortably in the safe zone (≥ 2.99), indicating low bankruptcy risk.
- Beneish M-Score of -2.54 suggests a low likelihood of earnings manipulation.
- Align Technology Inc converts about 15% of revenue into free cash flow — strong cash generation.
- At a valuation score of 75/100, ALGN trades near the cheapest end of its own historical range (P/E 25.3).
See how ALGN ranks on the Capex Tracker — top 50 capital spenders compared.
Recent Market Moves
See all ALGN moves →| Date | Session | Price | Move | Z-Score |
|---|---|---|---|---|
| Oct 15 | After-hours | 149.34 | +3.39% | 2.05 |
| Sep 22 | Regular | 153.18 | +4.29% | 2.72 |
| Sep 22 | After-hours | 153.86 | +4.75% | 2.99 |
Frequently Asked Questions about ALGN
What is the current Align Technology Inc (ALGN) stock price?
ALGN is trading at $147.31 at the last market close, down 1.36% on the session. PreMarketPrice tracks ALGN pre-market, intraday and after-hours prices.
Is ALGN stock a buy right now?
PreMarketPrice's quantitative model rates Align Technology Inc's financial health at 62/100. This is a data-driven snapshot of fundamentals, not investment advice.
Is ALGN stock overvalued?
Align Technology Inc trades at a trailing P/E of 25.3 and our valuation score rates it 75/100 (higher = cheaper vs. its own history). See the Valuation History and Key Metrics sections for forward P/E, EV/EBITDA and PEG context.
When does Align Technology Inc report earnings?
No confirmed earnings date is currently scheduled for ALGN. The Earnings section lists recent reports and updates as dates are announced.
What sector does Align Technology Inc operate in?
Align Technology Inc operates in the Healthcare sector, within the Orthopedic, Prosthetic & Surgical Appliances & Supplies industry. The Related Stocks section lists sector peers for comparison.
What does Align Technology Inc do?
Align Technology is the leading manufacturer of clear aligners.
About Align Technology Inc (ALGN) Stock
Align Technology Inc (ALGN) is a US-listed stock operating in the Healthcare sector, specifically the Orthopedic, Prosthetic & Surgical Appliances & Supplies industry. As of the latest update, Align Technology Inc is trading at $147.31, down 1.36% on the day with a market capitalization of $10.5 billion. The financial health score for ALGN is 62/100, which indicates good financial strength based on profitability, leverage, liquidity, and growth metrics. This page provides real-time pre-market pricing, earnings calendar, financial health analysis, and valuation metrics for ALGN stock.
ALGN Stock Analysis & Key Metrics
On PreMarketPrice, you can track Align Technology Inc (ALGN) across multiple dimensions:
- Pre-market price & movement: Real-time ALGN stock price with percentage change, updated continuously during pre-market and regular trading hours.
- Valuation & P/E history: Historical P/E, P/S, and P/B ratios for ALGN with trend analysis and normalized valuation multiples.
- Financial statements: Revenue, net income, assets, liabilities, and equity for Align Technology Inc across multiple reporting periods.
- Financial health score: A composite score of 62/100 based on Altman Z-Score, Piotroski F-Score, profitability, and leverage metrics for ALGN.
- Sector peers: Compare ALGN against 6 other healthcare stocks on key financial metrics.
Is ALGN a Good Stock to Buy?
This page provides data-driven analysis to help you evaluate Align Technology Inc (ALGN) as an investment. The financial health score of 62/100 suggests good financial fundamentals. Valuation metrics show whether the stock is trading above or below its historical average.However, this is not financial advice — always do your own research before investing.
Data on this page is sourced from real-time market feeds, Polygon.io, and Finnhub.Align Technology Inc (ALGN) trades on NYSE/NASDAQ. Pre-market trading occurs 4:00 AM – 9:30 AM ET. Regular market hours are 9:30 AM – 4:00 PM ET.